PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPYH. Price,B. Schultes, R. Prager,J. Fernandes,J.B. Møller,M. BlüherVALUE IN HEALTH（2018）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
